Loading...
•
Jun 30, 2022
Xeris Biopharma Q2 2022 Earnings Report
Posted record net revenue with strong demand for Gvoke HypoPen, Keveyis, and Recorlev.
Key Takeaways
Xeris Biopharma reported record net product revenue of $25.3 million for the second quarter of 2022, a 15% increase from Q1 2022 and a 34% increase from the same period last year on a pro forma basis. The company ended the quarter with $111.6 million in cash, cash equivalents, and short-term investments. Xeris Biopharma reaffirmed its full-year total net product revenue guidance of $105 million to $120 million.
Achieved record net product revenue of $25.3M, a 15% increase from Q1 2022 and a 34% increase from same period prior year on a pro forma basis.
Ended Q2 with $111.6M in cash, cash equivalents and short-term investments.
Gvoke prescriptions topped 34,000 for the first time, growing more than 60% compared to the same period in 2021.
Keveyis reported best quarter to date.
Revenue by Segment
Forward Guidance
Xeris Biopharma reaffirms full-year total net product revenue of $105M-$120M; $50M in synergies by year-end, 2022 year-end cash balance of $90M-$110M, and cash flow breakeven by year-end 2023
Positive Outlook
- Reaffirms full-year total net product revenue of $105M-$120M
- Expects $50M in synergies by year-end
- Projects 2022 year-end cash balance of $90M-$110M
- Anticipates cash flow breakeven by year-end 2023
- Gvoke market share continues to outpace the overall glucagon market
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...